313 related articles for article (PubMed ID: 35456991)
1. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
di Meo NA; Loizzo D; Pandolfo SD; Autorino R; Ferro M; Porta C; Stella A; Bizzoca C; Vincenti L; Crocetto F; Tataru OS; Rutigliano M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456991
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.
Putluri N; Shojaie A; Vasu VT; Vareed SK; Nalluri S; Putluri V; Thangjam GS; Panzitt K; Tallman CT; Butler C; Sana TR; Fischer SM; Sica G; Brat DJ; Shi H; Palapattu GS; Lotan Y; Weizer AZ; Terris MK; Shariat SF; Michailidis G; Sreekumar A
Cancer Res; 2011 Dec; 71(24):7376-86. PubMed ID: 21990318
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
4. Discovering biomarkers in bladder cancer by metabolomics.
Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).
Shahid M; Yeon A; Kim J
Mol Med Rep; 2020 Dec; 22(6):5003-5011. PubMed ID: 33174036
[TBL] [Abstract][Full Text] [Related]
6. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
7. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the metabolomic study of bladder cancer.
Amara CS; Vantaku V; Lotan Y; Putluri N
Expert Rev Proteomics; 2019 Apr; 16(4):315-324. PubMed ID: 30773067
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
10. Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
Rodrigues D; Pinto J; Araújo AM; Monteiro-Reis S; Jerónimo C; Henrique R; de Lourdes Bastos M; de Pinho PG; Carvalho M
Metabolomics; 2018 Apr; 14(5):62. PubMed ID: 30830384
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
12. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
13. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
14. Discovery of urine biomarkers for bladder cancer via global metabolomics.
Shi H; Li X; Zhang Q; Yang H; Zhang X
Biomarkers; 2016 Nov; 21(7):578-88. PubMed ID: 27133288
[TBL] [Abstract][Full Text] [Related]
15. Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.
Iliou A; Panagiotakis A; Giannopoulou AF; Benaki D; Kosmopoulou M; Velentzas AD; Tsitsilonis OE; Papassideri IS; Voutsinas GE; Konstantakou EG; Gikas E; Mikros E; Stravopodis DJ
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32164285
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic profiling of human bladder tissue extracts.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Krupa Z; Nizioł J
Metabolomics; 2024 Jan; 20(1):14. PubMed ID: 38267657
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Signatures of Treatment Response in Bladder Cancer.
Vieira de Sousa T; Guedes de Pinho P; Pinto J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139377
[TBL] [Abstract][Full Text] [Related]
18.
Plyushchenko IV; Fedorova ES; Potoldykova NV; Polyakovskiy KA; Glukhov AI; Rodin IA
J Proteome Res; 2022 Mar; 21(3):833-847. PubMed ID: 34161108
[TBL] [Abstract][Full Text] [Related]
19. NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation.
Gupta A; Bansal N; Mitash N; Kumar D; Kumar M; Sankhwar SN; Mandhani A; Singh UP
J Pharm Biomed Anal; 2020 May; 183():113134. PubMed ID: 32070930
[TBL] [Abstract][Full Text] [Related]
20. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Nieczaj A; Ruman T
Sci Rep; 2023 Jun; 13(1):9802. PubMed ID: 37328580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
